Latest Clinical & Research News
Specialty: Endocrinology
Brigham and Women’s Hospital researchers report an integrated analysis of 18 randomized, controlled trials of semaglutide (17,639 patients), concluding its safety and tolerability are now well characterized—and similar for the subcutaneous and oral formulations.
Read More...
Hyperkalemia is one of the most common adverse reactions to renin–angiotensin–aldosterone system inhibitor (RAASi) therapy. In a recent study, Brigham and Women’s Hospital researchers found that patients who develop hyperkalemia while receiving RAASi therapy have a higher risk of poor outcomes.
Read More...
Testosterone is a leading candidate for preventing and treating age-related loss of muscle mass, strength, power, and physical function. In this review, Brigham and Women’s Hospital researchers critically appraise several suppositions about using testosterone in older adults with functional limitations.
Read More...
Leaders from the Division of Endocrinology, Diabetes and Hypertension at Brigham and Women’s Hospital are honored to join international colleagues at the world’s premier event in endocrinology research and clinical care: the Endocrine Society Annual Meeting. ENDO 2023 takes place June 15–18 in Chicago, IL.
Read More...
The Brigham’s new approach to providing diabetes care for Latino/Hispanic patients involves embedding diabetes specialists in community clinics and offering culturally and linguistically appropriate services to help patients control their disease and its complications, as A. Enrique Caballero, MD, explains.
Read More...
Researchers at Brigham and Women’s Hospital have linked endoscopic gastric plication (also called distal primary obesity surgery endoluminal, or POSE) to significant improvement in liver-related outcomes in patients with obesity, nonalcoholic fatty liver disease, and clinically significant hepatic fibrosis.
Read More...
Few surgeons perform metabolic surgery for type 2 diabetes treatment, citing inadequate evidence, and for the same reason, many health insurance plans don’t cover it. Long-term supportive efficacy data from the largest randomized cohort has been published.
Read More...
A growing set of low-risk cancers, including early-stage thyroid and kidney cancers, is associated with excellent outcomes regardless of management strategy. Given the risks associated with overtreatment of these cancers, it follows that many patients should be treated nonoperatively. Read More
In the first large, population-based cohort study of the issue, researchers at Brigham and Women’s Hospital found 22% of eligible patients declined statin therapy initially and 6% never accepted the recommendation. Results on both measures were significantly higher for women than men.
Read More...
The Brigham’s Anand Vaidya, MD, MMSc, and Jenifer Michelle Brown, MD, have led studies showing that primary aldosteronism (PA) is much more prevalent than assumed—and may be a causative mechanism for 15%–24% of primary hypertension cases. Now, they are expanding PA screening among high-risk patient populations.
Read More...